Nanopharmaterial is a term by combining pharmaceuticalmaterial via nanotechnology. Here we demonstrate this concept by developing a novel nanopharmaterial, so called 177Lu-Gold nanostar (AuNS). 177Lu is a therapeutic radionuclide emitting moderate-energy beta particles as well as gamma rays for SPECT/CT-based imaging diagnosis. Nanostar can target tumors by enhanced permeability retention (EPR) effectsowns the photothermal therapeutic potent. The core technology is to integrate radionuclidenanomaterial to perform a new radio-nanopharmaterial for tumor target theranostic purpose.

Preparation of 177Lu-Gold nanostar is the core technology here. This radio-nanopharmaterial can combine with laser photothermal therapy to enhance the therapeutic efficacy, as Gold nanostar is not only a carrier but a therapeutic entity. Conjugation of 177LuGold nanostar is through DTPA chelator, a simple but biocompatible bridging method. Furthermore, 177Lu-Gold nanostar can be applied to tumor  using brachytherapy. It guarantees a high accumulation of this radio-nanopharmateriallow systemic toxicity.  This multi-modality theranostic approach will be important for precise medicine.

177Lu-Gold nanostar is essentially to demonstrate the concept of radio-nanopharmaterial. We expect to develop more novel radionuclides labeled nanopharmaterial in the future. Conventionally, nuclear medicine is important for diagnosistherapy in clinics. Hence, current techniques mainly contribute to the application field of biomedicine, specifically on the cancerous patients. However, we also anticipate to develop different types of 177Lu-Gold nanostars based on the biomarkers of various human diseases to broaden the application of this radio-nanopharmaterial.

天使投資人、策略合作夥伴